全文获取类型
收费全文 | 370篇 |
免费 | 21篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 15篇 |
妇产科学 | 24篇 |
基础医学 | 51篇 |
口腔科学 | 6篇 |
临床医学 | 17篇 |
内科学 | 65篇 |
皮肤病学 | 4篇 |
神经病学 | 35篇 |
特种医学 | 12篇 |
外科学 | 45篇 |
预防医学 | 34篇 |
眼科学 | 27篇 |
药学 | 13篇 |
肿瘤学 | 26篇 |
出版年
2023年 | 4篇 |
2022年 | 7篇 |
2021年 | 17篇 |
2020年 | 12篇 |
2019年 | 14篇 |
2018年 | 20篇 |
2017年 | 13篇 |
2016年 | 13篇 |
2015年 | 5篇 |
2014年 | 15篇 |
2013年 | 15篇 |
2012年 | 21篇 |
2011年 | 26篇 |
2010年 | 14篇 |
2009年 | 13篇 |
2008年 | 20篇 |
2007年 | 17篇 |
2006年 | 24篇 |
2005年 | 18篇 |
2004年 | 23篇 |
2003年 | 14篇 |
2002年 | 18篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 3篇 |
1998年 | 5篇 |
1997年 | 1篇 |
1995年 | 5篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 4篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1975年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有391条查询结果,搜索用时 46 毫秒
1.
Laura McGillis Nimish Mittal Daniel Santa Mina Joyce So Medha Soowamber Aliza Weinrib Leslie Soever Dmitry Rozenberg Louis Liu Yvonne Tse Joel Katz George S Charames Kieran Murphy Peter Vadas Maxwell P Slepian Scott Walsh Lindsay Wilson Arnon Adler Alyssa Franzese Laura Hussey Dayna‐Lynn Nevay Juan Guzman Hance Clarke 《American journal of medical genetics. Part A》2020,182(3):484-492
The new 2017 diagnostic criteria for hypermobile Ehlers–Danlos Syndrome (hEDS) provide a framework for diagnosing hEDS but are more stringent than the previous Villefranche criteria. Our clinical experience at the GoodHope EDS clinic was that the 2017 criteria left many highly symptomatic patients without a diagnosis of hEDS. We conducted a retrospective cohort study to confirm our clinic experience and assess the accuracy of the 2017 diagnostic criteria for hEDS in patients who had a previous hEDS diagnosis based on the Villefranche criteria. Our study found that 15% (n = 20 of 131) of patients with a prior diagnosis of hEDS met the 2017 diagnostic criteria, and many of the traits used to distinguish hEDS were not significantly more frequent in patients who met 2017 criteria versus those who did not. In both groups objective systemic manifestations were found less frequently than subjective systemic manifestations. Beighton score (BS) as assessed by primary care practitioner was found to be higher than assessment by EDS practitioner in 81% (n = 74 of 91) of cases. Generalized joint hypermobility was confirmed in only 46% (n = 51 of 111) of patients who had a previous diagnosis of hEDS. Higher BS did not correlate with increased number of systemic manifestations in our cohort. Common comorbidities of hEDS were found with similar frequency in those who met 2017 criteria and those who did not. Based on our cohort, the 2017 hEDS diagnostic criteria require refinement to improve its diagnostic accuracy. 相似文献
2.
3.
Oral anticoagulation and left atrial thrombi resolution in nonrheumatic atrial fibrillation or flutter: A systematic review and meta‐analysis
下载免费PDF全文
![点击此处可从《Pacing and clinical electrophysiology : PACE》网站下载免费的PDF全文](/ch/ext_images/free.gif)
4.
Aliza Hussain Wensheng Sun Anita Deswal James A. de Lemos John W. McEvoy Ron C. Hoogeveen Kunihiro Matsushita David Aguilar Biykem Bozkurt Salim S. Virani Amil M. Shah Elizabeth Selvin Chiadi Ndumule Christie M. Ballantyne Vijay Nambi 《Journal of the American College of Cardiology》2021,77(5):559-571
BackgroundAlthough intensive blood pressure reduction has cardiovascular benefits, the absolute benefit is greater in those at higher cardiovascular disease (CVD) risk.ObjectivesThis study examined whether N-terminal pro–B-type natriuretic peptide (NT-proBNP) helps identify subjects at higher risk for CVD events across systolic blood pressure (SBP), diastolic blood pressure (DBP), or pulse pressure (PP) categories.MethodsParticipants from the ARIC (Atherosclerosis Risk In Communities) study visit 4 (1996 to 98) were grouped according to SBP, DBP, or PP categories and further stratified by NT-proBNP categories. Cox regression models were used to estimate hazard ratios for incident CVD (coronary heart disease, ischemic stroke, or heart failure hospitalization) and mortality across combined NT-proBNP and/or BP categories, adjusting for CVD risk factors.ResultsThere were 9,309 participants (age: 62.6 ± 5.6 years; 58.3% women) with 2,416 CVD events over a median follow-up of 16.7 years. Within each SBP, DBP, or PP category, a higher category of NT-proBNP (100 to <300 or 300 pg/ml, compared with NT-proBNP <100 pg/ml) was associated with a graded increased risk for CVD events and mortality. Participants with SBP 130 to 139 mm Hg but NT-proBNP ≥300 pg/ml had a hazards ratio of 3.4 for CVD (95% confidence interval: 2.44 to 4.77) compared with a NT-proBNP of <100 pg/ml and SBP of 140 to 149 mm Hg.ConclusionsElevated NT-proBNP is independently associated with CVD and mortality across SBP, DBP, and PP categories and helps identify subjects at the highest risk. Participants with stage 1 hypertension but elevated NT-proBNP had greater cardiovascular risk compared with those with stage 2 SBP but lower NT-proBNP. Future studies are needed to evaluate use of biomarker-based strategies for CVD risk assessment to assist with initiation or intensification of BP treatment. 相似文献
5.
6.
7.
8.
9.
Avivit Cahn MD Itamar Raz MD Marc Bonaca MD Ofri Mosenzon MD Sabina A. Murphy MPH Ilan Yanuv MSc Aliza Rozenberg MA John P. H. Wilding MD Deepak L. Bhatt MD Darren K. McGuire MD Ingrid A. M. Gause-Nilsson MD Martin Fredriksson MD Peter A. Johansson MSc Gyorgy Jermendy MD Samy Hadjadj MD Anna Maria Langkilde MD Marc S. Sabatine MD Stephen D. Wiviott MD Lawrence A. Leiter MD 《Diabetes, obesity & metabolism》2020,22(8):1357-1368
10.
A Lipson N Alexopoulos GR Hartlage C Arepalli A Oeser A Bian T Gebretsadik A Shintani AE Stillman CM Stein P Raggi 《Atherosclerosis》2012,223(2):389-393
ObjectiveMorbidity and mortality secondary to premature cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) remain significant issues. The pathogenesis of CVD in SLE patients has not been fully explored. Epicardial adipose tissue (EAT) is believed to contribute to atherosclerosis development, through a paracrine and systemic inflammatory effect. We measured EAT volume in 162 SLE patients and 86 matched controls to assess the association of EAT with markers of atherosclerosis, cardiovascular risk and immunoactivation.MethodsClinical and laboratory characteristics collected included anthropomorphic measures, disease activity and damage indices, blood pressure measurement, lipid profile, inflammatory indices, adipokine levels and measures of adiposity. Coronary artery calcium (CAC) and EAT volume were measured using non-contrast cardiac computed tomography.ResultsEAT volume was greater in patients with SLE [(mean ± SD) 96.8 ± 45.9 cm3] than controls (78.2 ± 40.7 cm3; P = 0.001). The EAT volume was 31% larger (95% CI, 16.5%–47.4%) in SLE patients than controls (P < 0.001 adjusted for age, sex, and race; after additional adjustment for waist circumference P = 0.007). Within SLE patients, after adjusting for age, race, sex, and waist circumference, EAT volume was associated with cumulative corticosteroid dose (P = 0.007), current corticosteroid use (P < 0.001), HDL cholesterol (P = 0.033), and triglycerides (P = 0.005). EAT was significantly correlated with CAC score (P < 0.001), but the association was attenuated after adjustment for Framingham risk score (P = 0.051).ConclusionThe increased EAT volume seen in SLE patients is associated with corticosteroid use. Corticosteroids could have adverse cardiovascular effects in SLE via an increase in EAT volume, a marker of risk in the general population. 相似文献